http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary/Lung Disease Mini-Symposium
-
Pliant Therapeutics Inc. (PLRX) Appoints Katharine Knobil to its Board
-
Pliant Therapeutics Announces Appointment of Katharine Knobil, M.D. to Board of Directors
-
Pliant Therapeutics Announces Appointment of Katharine Knobil, M.D. to Board of Directors
-
Pliant Therapeutics Inc. (PLRX) Reports Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809
-
Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis
-
Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis
-
Pliant Therapeutics to Participate in Upcoming Investor Conferences
-
Pliant Therapeutics to Participate in Upcoming Investor Conferences
-
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
-
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
-
Pliant Therapeutics to Participate in BTIG Biotechnology Conference
-
Pliant Therapeutics to Participate in BTIG Biotechnology Conference
-
Pliant Therapeutics (PLRX) Granted FDA Fast Track Designation for PLN-74809
-
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Primary Sclerosing Cholangitis
-
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Primary Sclerosing Cholangitis
-
Pre-Open Movers: Twitter Sinks, DWAC Gains as Musk Walks Away from Deal
-
Pliant Therapeutics (PLRX) Reports Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809
-
Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis
-
Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis
-
Pliant Therapeutics Inc. (PLRX) Reports Presentation Highlighting Preclinical and Clinical Data in Support of the INTEGRIS-PSC Phase 2a Clinical Trial
-
Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022 Highlighting Preclinical and Clinical Data in Support of the INTEGRIS-PSC Phase 2a Clinical Trial
-
Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022 Highlighting Preclinical and Clinical Data in Support of the INTEGRIS-PSC Phase 2a Clinical Trial
-
Pliant Therapeutics Inc. (PLRX) Reports Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies
-
Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies
-
Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies
-
Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration
-
Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration
-
Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022
-
Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022
-
Pliant Therapeutics Announces Presentations at 2022 American Thoracic Society International Conference
-
Pliant Therapeutics Announces Presentations at 2022 American Thoracic Society International Conference
-
Pliant Therapeutics to Participate in Upcoming Investor Conferences
-
Pliant Therapeutics to Participate in Upcoming Investor Conferences
-
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
-
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
-
Pliant Therapeutics Inc. (PLRX) Enters $100M Loan Facility Agreement with Oxford Finance to Support Ongoing Development of PLN-74809
-
Pliant Therapeutics Enters into $100 million Loan Facility Agreement with Oxford Finance to Support Ongoing Development of PLN-74809
-
Pliant Therapeutics Enters into $100 million Loan Facility Agreement with Oxford Finance to Support Ongoing Development of PLN-74809
-
Pliant Therapeutics Inc. (PLRX) Granted FDA Fast Track Designation for PLN-74809 for the Treatment of Idiopathic Pulmonary Fibrosis
-
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Idiopathic Pulmonary Fibrosis
-
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Idiopathic Pulmonary Fibrosis
-
Pliant Therapeutics Announces Multiple Presentations at the 2022 American Thoracic Society International Conference
-
Pliant Therapeutics Announces Multiple Presentations at the 2022 American Thoracic Society International Conference
-
Pliant Therapeutics to Participate in Needham Healthcare Conference
-
Pliant Therapeutics to Participate in Needham Healthcare Conference
-
CORRECTION - Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
-
CORRECTION - Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
-
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
-
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
